Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals

laboratory-g614ff2fc9_1920

Volition's research and development activities are centered in Belgium. (Credit: Michal Jarmoluk from Pixabay)

VolitionRx Limited, a multi-national epigenetics company, announces the availability of its Nu.Q Vet Cancer Test through the IDEXX Laboratories, Inc. (“IDEXX”) reference laboratory network in the U.S.

Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: “IDEXX is a global leader in pet healthcare innovation and well-positioned to roll out the IDEXX Nu.Q Canine Cancer Screen worldwide. It is a simple, cost effective, easy to use blood test for screening older or ‘at risk’ dogs.

“Our Nucleosomics technology is easy to incorporate into annual wellness visits to support veterinarians in their clinical decision-making, enable earlier detection and treatment of cancer and improve the health and wellbeing of pets and pet owners.

“IDEXX’s launch of the Nu.Q Canine Cancer Screen in the U.S. this week, under our previously announced supply agreement, ultimately provides worldwide customer reach through its global reference laboratory network as we continue to commercialize our transformational Nu.Q technology within the companion animal healthcare sector, and capitalize on the significant opportunities available.”

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.

Source: Company Press Release